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To the Editor:
The American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA) 
recently published updated guidelines on the diagnosis and treatment of adults with 
community-acquired pneumonia (CAP).(1) In the 12 years since the previous edition of the 
guidelines, the importance of incorporating antimicrobial stewardship principles into 
treatment guidelines has been increasingly recognized.(2) In 2017, the United States (US) 
Healthcare Infection Control Practices Advisory Committee (HICPAC) provided guidance 
regarding this issue for US treatment guidelines. One of the recommendation states that 
“when multiple therapeutic options are available, a hierarchy of antibiotic treatment 
recommendations should be provided with ‘first choice’ options being those with adequate 
therapeutic efficacy, the lowest risk of facilitating antimicrobial resistance, and the lowest risk 
of promoting C. difficile and other adverse events, with consideration of healthcare value.”(3) 
The World Health Organization has recently developed the AWaRe (Access, Watch and 
Reserve) framework for classifying antibiotics based on antibiotic stewardship principles and 
recommends its use in treatment guidelines.(4, 5) 
We are therefore concerned that the 2019 version of the ATS/IDSA CAP guidelines seems to 
give disappointingly little weight to such antibiotic stewardship principles when continuing to 
recommend WHO Watch and Reserve antibiotics as first line options for CAP for most of the 
target populations. We suggest that Access antibiotics would be sufficient for many patients 
and preferable from an antibiotic stewardship perspective. Amoxicillin, the first-choice 
treatment for CAP based on the 2019 WHO Model List of Essential Medicines and listed also 
as first-choice option in many guidelines outside the USA, is recommended in the ATS’IDSA 
guidelines, together with doxycycline and macrolides as equivalent options, only 
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recommended for patients without comorbidities (very broadly stated as “chronic heart, lung, 
liver, or renal disease; diabetes mellitus; alcoholism; malignancy; or asplenia”).(6, 7) 
Since in the United States, 6 in 10 adults have one chronic disease and 4 in 10 adults have two 
or more chronic diseases, the recommendation for amoxicillin will be applicable to a minority 
of adults with CAP.(https://www.cdc.gov/chronicdisease/pdf/infographics/chronic-disease-
H.pdf) US physicians will therefore most likely continue to treat many patients with the Watch 
group respiratory fluroroquinolones - a class of antibiotic with well documented propensity 
to favour the emergence and spread of AMR and Clostridoides difficile infections, as well as 
an increased risk of adverse events (FDA alert).(8, 9) 
This will hamper CDC efforts to reduce overall antibiotic consumption and reduction of 
fluoroquinolone use in the United States.(10) The HICPAC antibiotic stewardship principles 
also suggest including recommendations for patient education on antibiotic therapy when 
appropriate. Accordingly, the CAP guidelines could have considered providing guidance to 
physicians on selection of Access group antibiotics such as amoxicillin or doxycycline for 
selected patients with stable comorbid conditions with close monitoring and adequate 
patient education. 
Even more surprising is the listing of the Reserve group fifth-generation cephalosporin 
ceftaroline as a first-choice empiric treatment option of CAP (in combination with a 
macrolide) in hospitalized adults without risk factors for MRSA and P. aeruginosa. Ceftaroline 
efficacy data from phase III trials suggesting superiority compared to ceftriaxone with regard 
to clinical cure require further scrutiny and its current listing as first-choice option violates 
basic antibiotic stewardship considerations.(11, 12) 
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Given that respiratory tract infections are one of the most frequent reasons for antibiotic 
prescriptions worldwide and that in many countries the United States treatment 
recommendations are still considered an important reference, it seems to us – as the WHO 
EML antibiotic working group - that this presents a lost opportunity for antibiotic stewardship. 
We believe there is a clear need for better alignment of all treatment guidelines to the same 
guiding principles and to reach a global set of evidence-based recommendations with a focus 
on enhancing the use of Access group antibiotics.
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